Activation of the PI3K/AKT pathway is detectable in 70–85% of patients with T-ALL, in roughly 5–10% of cases due to inactivating mutations of PTEN [53, 54]. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.